IDEXX Laboratories : Earnings snapshot Q2 2026

About this update from Idexx Laboratories, Inc.

‌Revenue Operating Profit Diluted Earnings Per Share $1,217M $426M $4.27 Reported growth: Organic growth: +10% +9% 35% of Revenue YoY change in basis points: Reported growth: +18% CAG Diagnostics Recurring Reported +140 bps Comparable growth: +15% Organic growth: +10% Comparable +110 bps CAG Water LPD Revenue $1,118M Revenue $59M Revenue $35M Reported growth: +9% Reported growth: +15% Reported growth: +11% Organic growth: +9% Organic growth: +13% Organic growth: +9% Net CAG Revenue Q2 Revenue Reported Growth year over year Organic Growth year over year Q2 Premium Instrument WW U.S. Intl Placements Catalyst 1,343 473 870 CAG Diagnostics Recurring $975M +11% +10% New and competitive 1,008 284 724 IDEXX VetLab™ Consumables $430M +15% +14% Second 334 189 145 Rapid Assay Products $102M +1% +1% Reference Laboratory Dx and $407M +11% +10% Premium Hematology 1,402 403 999 Consulting Services New and competitive 1,067 287 780 CAG Diagnostics Services and $36M +3% +2% Accessories Upgrades 335 116 219 CAG Diagnostics Capital - Instruments $47M -19% -20% SediVue Dx™ 918 343 575 Veterinary Software, Services and $96M +12% +12% Diagnostic Imaging Systems IDEXX inVue Dx™ 1,602 932 670 Recurring revenues $76M +11% +10% TOTAL 5,265 2,151 3,114 System and hardware $20M +18% +18% IDEXX Premium Instruments Installed Base (in thousands) 11% year over year Catalyst Premium Hematology 5% 8% SediVue IDEXX inVue Dx year over year 74.1 69.1 77.9 78.8 79.8 47.8 51.8 55.9 year over year 56.9 57.8 13% year over year 21.3 18.1 24.3 24.8 25.7 237% year over year 7.5 6.4 0.0 0.0 9.1 Q4 Q4 Q4 Q1 Q2 Q4 Q4 Q4 Q1 Q2 Q4 Q4 Q4 Q1 Q2 Q4 Q4 Q4 Q1 Q2 2023 2024 2025 2026 2023 2024 2025 2026 2023 2024 2025 2026 2023 2024 2025 2026 IDEXX Q2 2026 Earnings Highlights (NASDAQ: IDXX) ‌2026 Growth and Financial Performance Outlook Commentary Increases full year guidance midpoint to reflect strong CAG Diagnostics recurring revenue performance driven by IDEXX commercial execution, increases outlook for comparable operating margin expansion and EPS growth. Updates revenue guidance to $4,700 million - $4,745 million, 9.1% - 10.3% growth as reported and 8.5% - 9.7% organic, raising organic growth guidance at midpoint by 40 basis points vs. prior guide to reflect strong commercial performance. Revises reported operating margin outlook to 32.3% - 32.5%, reflecting 70 - 90 basis points of full-year comparable o...

View stock analysis, news, and events for Idexx Laboratories, Inc.